Bardet-Biedl Syndrome
12
3
4
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.3%
1 terminated out of 12 trials
85.7%
-0.8% vs benchmark
17%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (12)
The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK
Inherited Retinal Degenerative Disease Registry
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)
Early Genetic Identification of Obesity
Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Clinical Registry Investigating Bardet-Biedl Syndrome
COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study
Genetics and Clinical Characteristics of Bardet-Biedl Syndrome
Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement
Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults